Drug intelligence / Profile preview

si-FOLR1

Development stage: Preclinical
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

si-FOLR1 is a small interfering RNA (siRNA) designed to specifically target and inhibit the expression of Folate Receptor 1 (FOLR1). In colon cancer cells, the inhibition of FOLR1 by si-FOLR1 has been shown to decrease cell viability, promote sensitivity to oxaliplatin (L-OHP), and stimulate cell apoptosis. This action also leads to a decrease in the levels of ATP Binding Cassette Subfamily G Member 2 (ABCG2) and p-glycoprotein (p-gp).

Other names: small interfering RNA against FOLR1

Targets

FOLR1 (FRα)

Beyond the preview

Go deeper on si-FOLR1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on si-FOLR1.

Explore the full profile